scPharmaceuticals, which is commercializing an injectable version of an intravenous drug for heart failure, raised $90 million by offering 6.4 million shares at $14, the low end of the range of $14 to $16. scPharmaceuticals plans to list on the Nasdaq under the symbol SCPH. Jefferies, Leerink Partners and BMO Capital Markets acted as lead managers on the deal.
